ObjectiveEconomic evaluations predominantly use generic outcomes, such as EuroQol‐5 Dimension (EQ‐5D), to assess the health status. However, because of the generic nature, they are less suitable to capture the quality of life of patients with specific conditions. Given the transition to patient‐centered (remote) care delivery, this study aims to evaluate the possibility to use disease‐specific measures in a cost‐effectiveness analysis (CEA).MethodsA real‐life cohort from Maasstad Hospital (2020‐2021) in the Netherlands, with 772 Rheumatoid Arthritis (RA) patients, was used to assess the cost‐effectiveness of electronic consultations (e‐consultations) compared with face‐to‐face consultations. The Incremental Cost‐Effectiveness Ratio (ICER) based on the generic EQ‐5D was compared with ICER's based on RA specific measures; Rheumatoid Arthritis Impact of Disease (RAID) and Health Assessment Questionnaire‐Disability Index (HAQ‐DI). To compare the cost‐effectiveness of these different measures, HAQ‐DI and RAID were expressed in QALYs via estimated conversion equations.ConclusionsThe conventional ICER (e.g. EQ‐5D) indicates that e‐consultations are cost‐effective with cost savings of ‐ €161k per QALY gained for a prevalent RA cohort treated in a secondary trainee hospital. RA specific measures show similar results, with ICER's of ‐ €163k per HAQ‐DI(QALY) and ‐ €223k per RAID(QALY) gained. RA specific measures capture patient‐relevant domains and offer the opportunity to improve the assessment and treatment of the disease impact.DiscussionDisease‐specific patient‐reported outcome measures (PROMs) offer a promising alternative for traditional measures in economic evaluations, capturing patient‐relevant domains more comprehensively. As PROMs are increasingly applied in clinical practice, the next step entails modelling of a RA patient‐wide conversion equation to implement PROMs in economic evaluations.This article is protected by copyright. All rights reserved.